Mufemilast vs Prifemilast (HPP737)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriasis

Shared mechanism: PDE4 · full Psoriasis pipeline

Mufemilast

Marketed by Tianjin Hemay Pharmaceutical

Phase 3 in Psoriasissmall molecule
Partial signal

NCT04839328 · Phase 3 · completed

The study randomized 306 participants to Hemay005 or placebo, with participants masked to treatment, and used the clinical PASI75 response as its primary endpoint. Because no comparative results or statistical analysis are posted, the primary endpoint cannot be assessed.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Reported efficacy

Proportion of subjects who have 75% or more reduction in [Psoriasis area-and-severity index score (PASI)] (PASI75). (week 16): PASI75 比例分别为 53.6% vs 16.0%,sPGA 0/1 率分别为 31.3% vs 6.4% (PASI75 at week 16: Hemay005 53.6% vs placebo 16.0%; sPGA 0/1: 31.3% vs 6.4%) (met)

Result source: NCT04839328

Prifemilast (HPP737)

Developed by Newsoara Biopharma under a licence from vTv Therapeutics

Phase 3 in Psoriasissmall molecule
Partial signal

NCT07712731 · Phase 3 · completed

The trial randomized 607 participants to HPP737 or active treatment with apremilast and used triple masking of participants, care providers, and investigators. Its primary endpoints were clinical psoriasis measures.

Reported efficacy

To evaluate proportion of subjects at Week 16 achieving at least a 75% reduction(improvement) from baseline in PASI (Psoriasis Area and Severity Index) score (PASI 75); (From enrollment to end of treatment at 16 weeks); To evaluate proportion of subjects at Week 16 achieving sPGA (Static Physician's Global Assessment) rating of "clear (score 0) or almost clear (score 1)" (From enrollment to end of treatment at 16 weeks): Co-primary endpoints at week 16, prifemilast 20 mg once daily vs apremilast 30 mg twice daily: PASI 75 64.6% vs 35.3% and sPGA 0/1 55.6% vs 31.3% (both P<0.0001) (2026-10-09). (met)

Result source: NCT07712731

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointMufemilastPrifemilast (HPP737)
PASI 75—Not posted · NCT04839328—Not posted · NCT07712731
PASI 90—Not posted · NCT04839328—Not posted · NCT07712731
PASI 100—Not posted · NCT04839328—Not posted · NCT07712731
sPGA 0/1—Not posted · NCT04839328—Not posted · NCT07712731
DLQI, change—Not posted · NCT04839328—Not posted · NCT07712731

PASI 75

Mufemilast
—Not posted · NCT04839328
Prifemilast (HPP737)
—Not posted · NCT07712731

PASI 90

Mufemilast
—Not posted · NCT04839328
Prifemilast (HPP737)
—Not posted · NCT07712731

PASI 100

Mufemilast
—Not posted · NCT04839328
Prifemilast (HPP737)
—Not posted · NCT07712731

sPGA 0/1

Mufemilast
—Not posted · NCT04839328
Prifemilast (HPP737)
—Not posted · NCT07712731

DLQI, change

Mufemilast
—Not posted · NCT04839328
Prifemilast (HPP737)
—Not posted · NCT07712731
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Mufemilast
PASI75 比例分别为 53.6% vs 16.0%,sPGA 0/1 率分别为 31.3% vs 6.4% (PASI75 at week 16: Hemay005 53.6% vs placebo 16.0%; sPGA 0/1: 31.3% vs 6.4%) NCT04839328 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result
Prifemilast (HPP737)
Co-primary endpoints at week 16, prifemilast 20 mg once daily vs apremilast 30 mg twice daily: PASI 75 64.6% vs 35.3% and sPGA 0/1 55.6% vs 31.3% (both P<0.0001) (2026-10-09). NCT07712731 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result
The placebo-controlled Phase 3 was positive per the sponsor, with responses kept through 52 weeks; figures were not given (2026-10-09). NCT07712705 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Mufemilast's landscape · Prifemilast (HPP737)'s landscape